Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis

BACKGROUND: LTX-315 is an oncolytic peptide deriving from bovine lactoferrin, with the ability to induce cancer immunogenic cell death. However, the mechanism used by LTX-315 to trigger the antitumor immune response is still poorly understood. The expression of programmed cell death ligand 1 (PD-L1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Tianyu, Huang, Xing, Zhang, Gang, Lu, Minghao, Hong, Zhengtao, Wang, Meng, Huang, Junming, Zhi, Xiao, Liang, Tingbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921947/
https://www.ncbi.nlm.nih.gov/pubmed/35288467
http://dx.doi.org/10.1136/jitc-2021-004129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921947/
https://www.ncbi.nlm.nih.gov/pubmed/35288467
http://dx.doi.org/10.1136/jitc-2021-004129

Ejemplares similares